171 related articles for article (PubMed ID: 22051162)
1. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients.
Narita T; Yokoyama H; Yamashita R; Sato T; Hosoba M; Morii T; Fujita H; Tsukiyama K; Yamada Y
Diabetes Obes Metab; 2012 Mar; 14(3):283-7. PubMed ID: 22051162
[TBL] [Abstract][Full Text] [Related]
2. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
3. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
4. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients.
Narita T; Katsuura Y; Sato T; Hosoba M; Fujita H; Morii T; Yamada Y
Diabet Med; 2009 Feb; 26(2):187-8. PubMed ID: 19236625
[No Abstract] [Full Text] [Related]
5. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
Hiki M; Shimada K; Kiyanagi T; Fukao K; Hirose K; Ohsaka H; Fukushima Y; Kume A; Matsumori R; Sumiyoshi K; Miyazaki T; Ohmura H; Kurata T; Miida T; Daida H
Circ J; 2010 Jul; 74(7):1471-8. PubMed ID: 20519875
[TBL] [Abstract][Full Text] [Related]
6. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
[TBL] [Abstract][Full Text] [Related]
7. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus.
Nagai E; Katsuno T; Miyagawa J; Konishi K; Miuchi M; Ochi F; Kusunoki Y; Tokuda M; Murai K; Hamaguchi T; Namba M
Endocr J; 2011; 58(10):869-77. PubMed ID: 21869539
[TBL] [Abstract][Full Text] [Related]
8. Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. "the MASTER randomized, controlled trial".
Mikada A; Narita T; Yokoyama H; Yamashita R; Horikawa Y; Tsukiyama K; Yamada Y
Diabetes Res Clin Pract; 2014 Dec; 106(3):538-47. PubMed ID: 25451890
[TBL] [Abstract][Full Text] [Related]
9. Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
Shibata E; Aoki K; Tajima K; Taguri M; Terauchi Y
Expert Opin Pharmacother; 2016; 17(7):889-94. PubMed ID: 26918556
[TBL] [Abstract][Full Text] [Related]
10. Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men.
Aoki K; Miyazaki T; Nagakura J; Orime K; Togashi Y; Terauchi Y
Endocr J; 2010; 57(8):673-7. PubMed ID: 20519807
[TBL] [Abstract][Full Text] [Related]
11. Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.
Hariya N; Mochizuki K; Inoue S; Saito M; Fuchigami M; Goda T; Osonoi T
Drugs R D; 2014 Sep; 14(3):177-84. PubMed ID: 25079671
[TBL] [Abstract][Full Text] [Related]
12. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
[TBL] [Abstract][Full Text] [Related]
13. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Aoki K; Masuda K; Miyazaki T; Togashi Y; Terauchi Y
Endocr J; 2010; 57(8):667-72. PubMed ID: 20519806
[TBL] [Abstract][Full Text] [Related]
14. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
[TBL] [Abstract][Full Text] [Related]
16. The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
Hamada Y; Nagasaki H; Fuchigami M; Furuta S; Seino Y; Nakamura J; Oiso Y
Metabolism; 2013 May; 62(5):734-42. PubMed ID: 23194643
[TBL] [Abstract][Full Text] [Related]
17. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice.
Moritoh Y; Takeuchi K; Hazama M
J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898
[TBL] [Abstract][Full Text] [Related]
18. Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections.
Kato H; Ohta A; Kobayashi S; Ishii S; Sada Y; Kobayashi H; Ohmori S; Kondo A; Katabami T; Fuse J; Fukuda H; Nagai Y; Tanaka Y
Endocr J; 2012; 59(4):345-52. PubMed ID: 22301938
[TBL] [Abstract][Full Text] [Related]
19. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
[TBL] [Abstract][Full Text] [Related]
20. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
